NASDAQ:CNXU Conexeu Sciences (CNXU) Stock Price, News & Analysis $1.55 -0.53 (-25.48%) Closing price 11/20/2026 04:00 PM EasternExtended Trading$1.58 +0.02 (+1.61%) As of 11/20/2026 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsSEC Filings About Conexeu Sciences Stock (NASDAQ:CNXU) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Conexeu Sciences alerts:Sign Up Key Stats Today's Range$1.48▼$2.0950-Day Range$1.55▼$5.3052-Week Range$1.48▼$18.79Volume682,741 shsAverage Volume273,030 shsMarket Capitalization$43.73 millionP/E RatioN/ADividend YieldN/APrice Target$20.00Consensus RatingHold Company Overview Conexeu is a company focused on building a new class of collagen-based regenerative tissue products. The Company was incorporated on November 2, 2022 under the Business Corporations Act (British Columbia) and was continued out of British Columbia and domesticated into the State of Nevada under the laws of the State of Nevada on April 10, 2025. --- Conexeu is an early-stage medical device company formed to acquire and commercialize intellectual property ("IP") developed over more than a decade at the University of British Columbia (the "University") and the BC Professional Firefighters Burn and Wound Healing Laboratory. In November 2023, the Company entered into a patent assignment agreement with the University pursuant to which the Company acquired an assignment of the University's right, title, and interest in the applicable patents and patent applications related to the underlying technology. The Company's only device candidate is the CXU™ scaffold device candidate, which is in preclinical development and has not been approved or cleared for marketing in any jurisdiction. The Company is conducting preclinical research and preparing for regulatory engagement to evaluate potential use in wound care and other medical applications. Any potential benefits to patients, providers, or healthcare systems have not been established and will require further study and regulatory review. CXU™ is a temperature-responsive, collagen-based extracellular matrix ("ECM") formulation designed to transition from a liquid to a gel-like scaffold following topical application or injection, typically within approximately ten minutes (the "10 Minute Tissue™" concept). The device IP is protected by issued and pending patents and is being evaluated in preclinical studies for its ability to provide an ECM-like environment associated with cellular infiltration, vascularization, and organized tissue remodeling in non-clinical models. We intend to seek U.S. Food and Drug Administration ("FDA") clearance in the United States for the CXU™ scaffold device candidate through the 510(k) premarket notification process as a Class II medical device; however, the FDA has not yet determined the appropriate classification or regulatory pathway for our device candidate, may require additional data or a different pathway, and there can be no assurance that we will obtain clearance or that the device candidate will become commercially available. Our principal executive offices are located in Reno, Nevada. Read More Conexeu Sciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreCNXU MarketRank™: 2.478442280945 of 5 starsConexeu Sciences scored higher than 50% of companies evaluated by MarketBeat, and ranked 471st out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingConexeu Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialConexeu Sciences has a consensus price target of $20.00, representing about 1,190.3% upside from its current price of $1.55.Amount of Analyst CoverageConexeu Sciences has only been the subject of 1 research reports in the past 90 days.Read more about Conexeu Sciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Conexeu Sciences are expected to decrease in the coming year, from ($0.40) to ($0.53) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Conexeu Sciences is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Conexeu Sciences is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.52% of the float of Conexeu Sciences has been sold short.Short Interest Ratio / Days to CoverConexeu Sciences has a short interest ratio ("days to cover") of 1.12, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Conexeu Sciences has recently increased by 44.61%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldConexeu Sciences does not currently pay a dividend.Dividend GrowthConexeu Sciences does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.42 News SentimentConexeu Sciences has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Conexeu Sciences this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for CNXU on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows17 people have added Conexeu Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 21% compared to the previous 30 days. Company Ownership2.9 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $499,998.00 in company stock, which represents 1.1435% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Conexeu Sciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $499,998.00 in company stock and sold $0.00 in company stock.Percentage Held by InstitutionsConexeu Sciences has minimal institutional ownership at this time.Read more about Conexeu Sciences' insider trading history. Receive CNXU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Conexeu Sciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CNXU Stock News HeadlinesConexeu Sciences Inc. Announces Appointment of Daniel M. Bradbury as Chairman of the Board of Directors, Effective December 1, 2026November 19 at 11:39 AM | marketscreener.comMConexeu Sciences Appoints Life Sciences Veteran Daniel M. Bradbury as Chairman of the Board of DirectorsNovember 19 at 8:30 AM | globenewswire.comThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This past May, flooding cut the supply route into the largest uranium complex on the planet, and in July Cigar Lake went down a second time. Gerardo Del Real calls this the Third Convergence Event and has backed three small companies positioned in front of it.November 21 at 1:00 AM | Digest Publishing (Ad)Conexeu Begins Developing Sheet, Lattice Formats Of CXU Wound-Care PlatformNovember 18 at 1:08 PM | rttnews.comConexeu Sciences Announces Early-Stage Development of W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice, Fabricated Formats of Its Investigational CXU™ PlatformNovember 18 at 7:34 AM | markets.businessinsider.comConexeu Sciences Inc. Announces Early-Stage Development of W.A.F.E.R. Sheet and W.A.F.E.R. Lattice Fabricated Formats of Its Investigational CXU PlatformNovember 17, 2026 | marketscreener.comMConexeu Sciences Announces Development of W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice to Expand CXU™ Wound Care PlatformNovember 17, 2026 | quiverquant.comQConexeu Sciences Announces Early-Stage Development of W.A.F.E.R.™ Sheet and W.A.F.E.R.November 17, 2026 | globenewswire.comSee More Headlines CNXU Stock Analysis - Frequently Asked Questions How have CNXU shares performed this year? Conexeu Sciences' stock was trading at $14.40 on May 23, 2026. Since then, CNXU stock has decreased by 89.2% and is now trading at $1.55. How were Conexeu Sciences' earnings last quarter? Conexeu Sciences Inc. (NASDAQ:CNXU) released its quarterly earnings data on Monday, September, 14th. The company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.19. When did Conexeu Sciences IPO? Conexeu Sciences (CNXU) raised $38 million in an initial public offering (IPO) on Thursday, May 21st 2026. The company issued 9,481,123 shares at $4.00 per share. How do I buy shares of Conexeu Sciences? Shares of CNXU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Conexeu Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Conexeu Sciences investors own include NVIDIA (NVDA), Palantir Technologies (PLTR), SpaceX (SPCX), Tesla (TSLA), Corning (GLW), IonQ (IONQ) and Rocket Lab (RKLB). Company Calendar Last Earnings9/14/2026Today11/21/2026Fiscal Year End10/31/2027Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Healthcare Equipment & Supplies Sub-IndustryHealthcare Equipment Current SymbolNASDAQ:CNXU CIK2066836 Webwww.conexeu.com Phone(604) 315-4722FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Price Target for Conexeu Sciences$20.00 High Price Target$20.00 Low Price Target$20.00 Potential Upside/Downside+1,190.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.92 million Net MarginsN/A Pretax MarginN/A Return on Equity-200.20% Return on Assets-177.26% Debt Debt-to-Equity RatioN/A Current Ratio5.31 Quick Ratio5.31 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares28,210,000Free FloatN/AMarket Cap$43.73 million OptionableN/A BetaN/A 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:CNXU) was last updated on 11/20/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredELON + YOU + DECEMBER 8THElon Musk's next big project may be the most ambitious move of his career, and all signs point to December 8th...Paradigm Press | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Conexeu Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Conexeu Sciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.